Last updated: March 2026
IGF-1 DES (Des(1-3) IGF-1) is a naturally occurring truncated form of insulin-like growth factor 1 that lacks the first three amino acids. This deletion eliminates IGFBP binding entirely and produces ~10-fold greater potency at the IGF-1 receptor — making it a uniquely powerful tool for site-specific muscle growth research via local intramuscular injection.
IGF-1 DES is naturally produced in the brain and other tissues as a splice variant — nature's own high-potency, locally-acting IGF-1. Its 3 amino acid truncation removes the tripeptide (Gly-Pro-Glu) that normally anchors binding to IGFBPs, freeing the molecule to interact directly with the IGF-1 receptor at far higher efficiency.
Removing the Gly-Pro-Glu tripeptide from position 1-3 of IGF-1 eliminates binding to all six IGF binding proteins. In plasma, native IGF-1 is ~97-99% bound to IGFBPs (primarily IGFBP-3). IGF-1 DES is essentially 100% free — every molecule is bioavailable for receptor binding. This explains the dramatic potency increase.
The very short half-life (~20-30 min) of IGF-1 DES in circulation means that intramuscular injection near a target muscle results in high local IGF-1R activation with limited systemic distribution. This theoretical site-specificity is why researchers inject directly into or adjacent to the target muscle immediately post-workout.
At 10× the potency of native IGF-1, DES powerfully activates IGF-1 receptor signaling in muscle satellite cells, driving both hypertrophy (existing fiber growth via mTOR) and hyperplasia (new fiber formation). In animal models, local IGF-1 DES injection produces local muscle growth significantly beyond contralateral control limbs.
IGF-1 DES was first identified in human fetal brain tissue. The brain produces this truncated form locally as an autocrine/paracrine growth signal. Its natural occurrence lends biological plausibility, though synthetic administration for muscle growth is experimental with no approved therapeutic application or long-term human safety data.
Primarily in vitro cell studies and animal models. IGF-1 DES is a research tool; human clinical trial data is absent.
Research and injection supplies for IGF-1 DES site-injection protocols.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational and research purposes only. IGF-1 DES is not approved for human use. All evidence is from in vitro cell studies and animal experiments. No human clinical trials exist for muscle-building applications. Consult a qualified physician before considering any peptide or growth factor compound.